Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei

Memo - Magazine of European Medical Oncology

Volumn 2, Issue 2, 2009, Pages 113-115

  Sun, W L ^a,b   Hutarew, G ^c   Gradl, J ^d   Gratzl, M ^a   Heumader, E ^a   Denz, H ^a   Fiegl, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bevacizumab; Metronomic therapy; Pseudomyxoma peritonei

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PREGABALIN;

ADULT; ANGIOGENESIS; APPENDIX TUMOR; ARTICLE; CASE REPORT; CYTOREDUCTIVE SURGERY; DEPRESSION; DISEASE COURSE; DRUG MECHANISM; FATIGUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; MALE; MULTIPLE CYCLE TREATMENT; PERITONEUM PSEUDOMYXOMA; POLYNEUROPATHY; PRIORITY JOURNAL; STOMATITIS; TREATMENT RESPONSE; VILLOUS ADENOMA;

EID: 77953461495     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-009-0113-y     Document Type: Article

References (19)

1. BM Ronnett BM Shmookler M Diener-West, et al. 1997 Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women Int J Gynecol Pathol 16 1 9 8986525 1:STN:280:DyaK2s7jvF2mtg%3D%3D
2. C Szych A Staebler DC Connolly, et al. 1999 Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women Am J Pathol 154 1849 1855 10362811 1:STN:280:DyaK1M3ptlSgsA%3D%3D
3. BM Ronnett H Yan RJ Kurman, et al. 2001 Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis Cancer 92 85 91 11443613 10.1002/1097-0142(20010701)92:1<85:: AID-CNCR1295>3.0.CO;2-R 1:STN:280:DC%2BD3MzovVyisQ%3D%3D (Pubitemid 32623044)
4. PH Sugarbaker D Chang 1999 Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy Ann Surg Oncol 6 727 731 10622499 10.1007/s10434-999-0727-7 1:STN:280:DC%2BD3c%2Fos1aisw%3D%3D
5. RM Smeenk VJ Verwaal N Antonini, et al. 2007 Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Ann Surg 245 104 109 17197972 10.1097/01.sla.0000231705.40081.1a (Pubitemid 46035441)
6. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
7. SB Wedam JA Low SX Yang, et al. 2006 Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 769 777 16391297 10.1200/JCO.2005.03.4645 1:CAS:528: DC%2BD28XitVGisbY%3D (Pubitemid 46622044)
8. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
9. B Escudier A Pluzanska P Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 18156031 10.1016/S0140-6736(07)61904-7 (Pubitemid 350296300)
10. K Prassl A Sahanic B Reicher, et al. 2008 Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation memo 1 149 151 10.1007/s12254-008-0051-0
11. S van Ruth AA Hart JM Bonfrer, et al. 2002 Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy Ann Surg Oncol 9 961 967 12464587 10.1007/BF02574513
12. TJ Miner J Shia DP Jaques, et al. 2005 Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy Ann Surg 241 300 308 15650641 10.1097/01.sla.0000152015.76731.1f
13. AT Byrne L Ross J Holash, et al. 2003 Vascular endothelial growth factor trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clin Cancer Res 9 5721 5728 14654557 1:CAS:528:DC%2BD3sXpsVeju70%3D
14. L Hu J Hofmann C Zaloudek, et al. 2002 Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer Am J Pathol 161 1917 1924 12414537 1:CAS:528:DC%2BD38XptV2gur4%3D
15. RA Burger MW Sill BJ Monk, et al. 2007 Phase II trial of Bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study J Clin Oncol 25 5165 5171 18024863 10.1200/JCO.2007.11.5345 1:CAS:528:DC%2BD2sXhsVKnsb%2FE (Pubitemid 350237599)
16. CG Willett Y Boucher E di Tomaso, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 14745444 10.1038/nm988 1:CAS:528: DC%2BD2cXoslKmtQ%3D%3D (Pubitemid 38524883)
17. T Inai M Mancuso H Hashizume, et al. 2004 Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am J Pathol 165 35 52 15215160 1:CAS:528:DC%2BD2cXmtFygsrc%3D
18. MR Mancuso R Davis SM Norberg, et al. 2006 Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2610 2621 17016557 10.1172/JCI24612 1:CAS:528:DC%2BD28XhtVKgu7rO (Pubitemid 44511625)
19. AA Garcia H Hirte G Fleming, et al. 2008 Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 76 82 18165643 10.1200/JCO.2007.12.1939 1:CAS:528:DC%2BD1cXhsVCrsLc%3D